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Acid-base profile in patients on PD. Secular trends in dialy-
sis dose in peritoneal dialysis (PD) and modes of dialysis de-
livery [automated PD (APD) versus continuous ambulatory
PD (CAPD)] require a reexamination of acid-base status in
patients treated with these renal replacement modalities. We
explored steady-state acid-base profile and its determinants in
175 patients on CAPD and 77 patients on APD. The major-
ity (62% to 70%) of patients had serum bicarbonate levels
in the normal range, and a minority (17% to 27%) had val-
ues just above 28 mEq/L. Only a small percentage (10% to
12%) of patients in either the CAPD or the APD groups had a
serum HCO3 less than 22 mEq/L, an indication of the successful
correction of acidosis in most patients. The anion gap was ele-
vated (>16 mEq/L) in the majority of patients on CAPD and
APD and bore an inverse relationship to serum HCO3 and a
direct relationship to serum albumin and serum phosphate. In
CAPD patients, but not APD patients, a significant inverse re-
lationship was observed between the anion gap and peritoneal
permeability as assessed by four-hour D/Pcreatinine. The correc-
tion of acidosis in PD appears to be predominantly achieved
by the continuous supplementation of alkali via dialysis, with
residual renal function not differentiating the degree of cor-
rection. Steady-state serum bicarbonate in patients on CAPD
appeared to be responsive to the underlying peritoneal mem-
brane permeability characteristics of the patient that govern
alkali loss and gain, but the higher dialysate volumes in APD
appear to override this effect. Higher albumin, blood urea ni-
trogen (BUN), and phosphate in patients with lower HCO3
suggest a discrepancy between daily acid load and dialysis
dose.
Acidosis is one of the cardinal manifestations of re-
nal failure and its correction is one of the elementary
and obvious goals of renal replacement therapy. A vari-
ety of studies have examined the correction of acidosis
and the relevance of such corrections on the health of pa-
tients on dialysis [1–20]. While these contributions have
greatly advanced our understanding of mechanisms of
generation and correction of acidosis [13, 14], the ongoing
changes in dialysis technology as to delivery modes and
changing buffer use in both hemodialysis (HD) and peri-
toneal dialysis (PD) require that examination of contem-
porary patient groups be undertaken to delineate current
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successes. Changes in buffer sources have been under-
taken in both HD (from acetate to bicarbonate) and in
PD (from acetate to lactate, and to bicarbonate alone or
supplemented with lactate) [1, 3, 6–10, 12]. Furthermore,
changes in dialysis dose (increasing in both HD and PD)
[21–28], dialysis frequency (shorter times in in-center HD
and the emergence of short daily and nocturnal HD), and
modifications in dialysis delivery modes (an increasing
use of APD), may have an impact on the correction of
uremic acidosis. It is the aim of the present paper to exam-
ine the status of acidosis correction in patients on PD and
compare the effects of CAPD, APD, and patient factors
that may modulate response to alkali therapy delivered
by dialysis.
METHODS
The present analysis is based on cohorts of patients
originally recruited to participate in a randomized con-
trolled trial for the evaluation of a new dialysis solu-
tion [29, 30]. Only measurements obtained at baseline
while patients were on standard dialysis regimen and
solution are considered herein. The criteria for patient
selection, and hence, inclusion in the current analysis,
were as follows: (1) Patients who had given written in-
formed consent; (2) patients who were at least 18 years
old; (3) patients who were treated with PD for at least
90 days before the screening visit; and (4) patients whose
standard prescription was stable for at least 30 days prior
to the screening visit.
The following patients were excluded from the study
and hence the present analysis: (1) Patients who had an
acute or chronic exit site or tunnel infection; (2) patients
who required antibiotics for the treatment of an episode
of peritonitis in the 30 days prior to the screening visit;
(3) patients who were known to be HIV positive; (4) pa-
tients who had other serious disease such as active ma-
lignancy, or, if previously treated, residual malignancy
or systemic infection; (5) patients who had active liver
disease such as cirrhosis of the liver, active hepatitis, or
other active liver disease; (6) patients who had an ill-
ness or injury requiring hospitalization during the 30 days
preceding the screening visit; and (7) patients who were
pregnant or lactating. It is recognized that any and each
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Table 1. Overall demographic profile
Parameter CAPD APD P value
N 175 77
Age 55.29 ± 1.05 52.68 ± 1.66 NS
Height 165.2 ± 0.9 170.1 ± 1.1 0.002
Weight 76.0 ± 1.2 81.2 ± 1.8 0.018
M:F 60:115 49:28
Duration of dialysis years 2.15 ± 0.16 3.96 ± 0.54 0.001
Data are mean ± SE.
Table 2. Overall biochemical profile
Parameter CAPD APD
N 175 77
BUN mg/dL 51.08 ± 1.24 50.12 ± 1.92
Creatinine mg/dL 9.67 ± .28 10.96 ± .49
Na mEq/L 137.71 ± .27 138.40 ± .44
K mEq/L 3.91 ± .05 3.84 ± .07
Cl mEq/L 95.07 ± .33 95.45 ± .46
HCO3 mEq/L 25.30 ± .24 25.73 ± .36
AGAP mEq/L 21.23 ± .30 20.97 ± .515
Ca mg/dL 9.44 ± .06 9.29 ± .10
PO4 mg/dL 5.07 ± .11 5.21 ± .19
Albumin g/dL 3.21 ± .04 3.27 ± .0521
Cholesterol mg/dL 206.36 ± 3.72 200.12 ± 4.84
Data are mean ± SE. Abbreviations are: BUN, blood urea nitrogen; Na,
sodium; K, potassium; Cl, chloride; HCO3, bicarbonate; AGAP, anion gap; Ca,
calcium; PO4, phosphate.
of the above exclusion conditions can have an effect on
patient acid-base balance.
As part of their baseline evaluation, all patients de-
scribed had standard blood chemistry and hematology
measures, as well as a standard peritoneal equilibra-
tion test (PET). All patients, who had urine output
>100 mL/24 hours, collected their 24-hour urine output
during the 24 hours preceding baseline. Urea nitrogen
and creatinine were used to determine the residual renal
function (RRF). RRF was calculated as the average of re-
nal creatinine clearance (CrCl) and renal urea nitrogen
clearance (Ucl) by standard formulas.
RESULTS
General characteristics of the population
The overall profile of the study population is illustrated
in Tables 1–3. The demographic characteristics of this
population are similar to the dialysis population in North
America in general and can thus be considered as repre-
sentative of the state of stable patients on PD. Patients
on APD were slightly larger than patients on CAPD, had
lower residual renal function (RRF), and used a higher
volume of dialysis solution daily. All of these differences
reflect common practice patterns in North America.
A small percentage (10% to 12%) of patients in ei-
ther the CAPD or the APD groups had a serum HCO3
less than 22 mEq/L, an indication of the successful cor-
rection of acidosis in most patients. The majority (62% to
Table 3. Overall renal and dialytic profile
Parameter CAPD APD
N 175 77
Urine volume mL/24 hr 718 ± 56 510 ± 61
CrCl mL/min 5.23 ± .45 2.22 ± .48
Urea Cl mL/min 2.53 ± .20 .96 ± .19
RRF mL/min 3.88 ± .31 1.59 ± .31
Dialysis volume mL/24 hr 9356 ± 112 14172 ± 314
4-hour D/Pcreatinine .67 ± .01 .69 ± .01
D4/D0glucose .38 ± .01 .39 ± .02
4-hour D/Purea .89 ± .01 .90 ± .01
PET-UF mL/4 hr 436 ± 16 352 ± 26
LD-UF mL 294 ± 27 303 ± 45
Data are mean ± SE. Abbreviations are: CrCl, creatinine clearance;
urea Cl, urea clearance; RRF, average of creatinine and urea clearances;
4-hour D/Pcreatinine, ratio of dialysate creatinine at 4 hours of dwell to serum
creatinine; D4/D0glucose, ratio of 4-hour dialysate glucose to 0 hour dialysate
glucose; 4-hour D/Purea, ratio of dialysate urea at 4 hours of dwell to BUN;
PET-UF, net ultrafiltration during a 4-hour PET with 2.5% dextrose solution;
LD-UF, net ultrafiltration during an overnight dwell with 2.5% dextrose solution.
70%) of patients had serum bicarbonate levels in the nor-
mal range, and a small group (17% to 27%) had values
just above 28 mEq/L (Fig. 1). The anion gap was ele-
vated (>16 mEq/L) in the majority of patients on CAPD
and APD (Fig. 2) and bore an inverse relationship to
serum HCO3 (Fig. 3) and a direct relationship to serum
albumin (Fig. 4) and serum phosphate (Fig. 5). In CAPD
patients, but not APD patients, a significant inverse rela-
tionship was observed between the anion gap and peri-
toneal permeability as assessed by four-hour D/Pcreatinine
(Fig. 6). The correlation between the anion gap and albu-
min in CAPD patients (r = 0.403, P < 0.001) was reduced
when it was controlled for phosphate levels (r = 0.363,
P < 0.001), but remained significant and was further re-
duced when controlled for both phosphate and four-hour
D/Pcreatinine (r = 0.276, P < 0.001). In APD patients, how-
ever, the correlation between albumin and the anion gap
(r = 0.543, P < 0.001) was minimally affected by control-
ling for phosphate (r = 0.528, P < 0.001) or both phos-
phate and four-hour D/Pcreatinine (r = 0.516, P < 0.001).
In CAPD patients, the correlation between the anion
gap and four-hour D/Pcreatinine (r = −0.319, P < 0.001)
was reduced but remained significant when it was con-
trolled for phosphate (r =−0.269, P < 0.001). Controlling
for albumin, however, abolished the correlation between
the anion gap and the four-hour D/Pcreatinine (r = −0.103,
P = ns). In neither CAPD nor APD did the dialysis solu-
tion volume correlate with any of the biochemical mark-
ers of interest, either absolute or factored for body weight
or height.
Profile by residual renal function
Because renal function plays a crucial role in acid ex-
cretion, the impact of residual renal function (RRF) on
the acid-base status of patients on dialysis was exam-
ined to explore whether the effects of continuous dialysis
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Fig. 1. Distribution of serum HCO3 values in patients on continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis
(APD). Numerals within each bar reflect number of patients falling within the indicated interval.
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Fig. 2. Distribution of serum anion gap values in patients on continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis
(APD). Numerals within each bar reflect number of patients falling within the indicated interval.
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Fig. 3. Inverse significant correlations were observed between serum HCO3 and anion gap in continuous ambulatory peritoneal dialysis (CAPD)
and automated peritoneal dialysis (APD) patients.
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Fig. 4. Direct significant correlations were observed between serum albumin and anion gap in continuous ambulatory peritoneal dialysis (CAPD)
and automated peritoneal dialysis (APD) patients.
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Fig. 5. Direct significant correlations were observed between serum phosphate and anion gap in continuous ambulatory peritoneal dialysis (CAPD)
and automated peritoneal dialysis (APD) patients.
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Fig. 6. Inverse significant correlations were observed between four-hour D/Pcreatinine and anion gap in continuous ambulatory peritoneal dialysis
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were dominant, or whether the role of RRF was still ap-
parent in the face of continuous alkali supplementation.
Among patients on CAPD, 86 had measurable urine out-
put (mean ± SE, 718 ± 56 mL/24 h) and consequently
measurable renal function (CrCl, 5.1 ± 0.4 mL/min;
urea Cl, 2.5 ± 0.2 mL/min; RRF, 3.8 ± 0.3 mL/min),
and 87 patients were considered anuric. The two groups
were comparable for demographic characteristics (except
for duration on dialysis, which was longer in the anuric
patients: 2.85 ± .3 vs. 1.45 ± .1 years, P < 0.001). On exam-
ination of biochemical profile, albumin, blood urea nitro-
gen, cation levels (calcium, phosphate), electrolytes (Na,
K, Cl, HCO3) and anemia control were similar between
the two groups. Serum bicarbonate levels were equiv-
alent (25.3 ± 0.3 vs. 25.3 ± 0.3 mEq/L), but the anion
gap was slightly higher in the anuric group (22.1 ± 0.5
vs. 20.3 ± 0.4 mEq/L, P < 0.01). The other notable differ-
ence between the two groups was serum creatinine, which
was higher in the anuric patients compared with those
with RRF (11.0 ± 0.4 vs. 8.3 ± 0.3 mg/dL, respectively,
P < 0.001).
Among patients on APD, 39 had measurable urine out-
put (mean ± SE, 510 ± 61 mL/24 h) and consequently
measurable renal function (CrCl, 4.4 ± 0.8 mL/min; urea
Cl, 1.9 ± 0.3 mL/min; RRF, 3.1 ± 0.5 mL/min), and
38 patients were considered anuric. The two groups were
comparable for demographic characteristics (except for
duration on dialysis, which was longer in the anuric pa-
tients). On examination of biochemical profile, albumin,
blood urea nitrogen, cation levels (calcium, phosphate),
electrolytes (Na, K, Cl, HCO3) and anemia control were
similar between the two groups. Serum bicarbonate lev-
els were equivalent (25.6 ± 0.6 vs. 25.9 ± 0.5 mEq/L) and
so were the anion gaps (20.7 ± 0.7 vs. 21.2 ± 0.7 mEq/L).
The only notable difference between the two groups was
serum creatinine, which was higher in the anuric patients
compared with those with residual renal function (13.4 ±
0.7 vs. 8.6 ± 0.5 mg/dL, respectively, P < 0.001).
Profile by HCO3 level
To gain better insight into the factors underlying the
broad range of values of bicarbonate, the CAPD and
APD groups were further subdivided into subsets based
on serum bicarbonate levels (Tables 4–7). In CAPD pa-
tients, those with HCO3 lower than 22 had higher blood
urea nitrogen (BUN), anion gap, phosphate, and choles-
terol than the other two groups (P < 0.001 to P < 0.015)
(Figs. 7 and 8). Furthermore, albumin levels were higher
than the other two groups but were statistically differ-
ent only compared with the high HCO3 group (P < 0.05)
(Fig. 9). These differences in biochemical profile were
paralleled by differences in peritoneal membrane char-
acteristics, with the low bicarbonate group being char-
acterized by lower membrane permeability and higher
Table 4. CAPD biochemical profile by HCO3 status
Parameter HCO3<22 22≤ HCO3<28 HCO3≥28
N% 22 (12.6%) 122 (70.1%) 30 (17.3%)
BUN mg/dL 64.1 ± 3.9∗ 50.3 ± 1.4 44.5 ± 2.6
Creatinine mg/dL 10.8 ± .9 9.4 ± .3 9.75 ± .7
Na mEq/L 136.6 ± .8 137.7 ± .3 138.8 ± .5
K mEq/L 3.96 ± .13 3.94 ± .06 3.70 ± .11
Cl mEq/L 95.2 ± 1.2 94.9 ± .4 95.7 ± .7
HCO3 mEq/L 20.3 ± .2a 24.9 ± .1 30.2 ± .4
AGAP mEq/L 25.0 ± .9a 21.7 ± .3 16.6 ± .7
Ca mg/dL 9.4 ± .18 9.4 ± .07 9.5 ± .18
PO4 mg/dL 5.8 ± .3b 5.0 ± .1 4.6 ± .2
Albumin g/dL 3.37 ± .11 3.22 ± .04 3.04 ± .11
Cholesterol mg/dL 230 ± 12 205 ± 4 194 ± 8
Data are mean ± SE. Abbreviations are: BUN, blood urea nitrogen; Na,
sodium; K, potassium; Cl, chloride; HCO3, bicarbonate; AGAP, anion gap; Ca,
calcium; PO4, phosphate.
aP < 0.0001 vs. each of the other two groups; bP < 0.0001 vs. HCO3>28 group
Table 5. CAPD renal and dialytic profile by HCO3 status
Parameter <22 22 ≤x <28 ≥28
N% 22 (12.6%) 122 (70.1%) 30 (17.3%)
Urine volume mL/24 hr 354 ± 111 364 ± 47 363 ± 96
CrCl mL/min 2.42 ± .87 2.46 ± .31 3.19 ± .96
Urea Cl mL/min 2.20 ± .61 2.55 ± .22 2.65 ± .54
RRF mL/min 3.76 ± 1.00 3.78 ± .32 4.32 ± .96
Dialysis volume mL/24 hr 9295 ± 302 9290 ± 1370 9716 ± 260
4-hour D/Pcreatinine .61 ± .01 .67 ± .01 .71 ± .02
D4/D0glucose .42 ± .01 .38 ± .007 .35 ± .01
4-hour D/Purea .86 ± .01 .89 ± .007 .90 ± .01
PET-UF mL/4 hr 555 ± 46 435 ± 19 345 ± 31
LD-UF mL 579 ± 71 262 ± 32 200 ± 62
Data are mean ± SE. Abbreviations are: CrCl, creatinine clearance;
urea Cl, urea clearance; RRF, average of creatinine and urea clearances;
4-hour D/Pcreatinine, ratio of dialysate creatinine at 4 hours of dwell to serum
creatinine; D4/D0glucose, ratio of 4-hour dialysate glucose to 0 hour dialysate
glucose; 4 hour D/Purea, ratio of dialysate urea at 4 hours of dwell to BUN;
PET-UF, net ultrafiltration during a 4-hour PET with 2.5% dextrose solution;
LD-UF, net ultrafiltration during an overnight dwell with 2.5% dextrose solution.
ultrafiltration response than the other two groups (P <
0.01 for all comparisons). Patients in the intermediate
HCO3 group differed from the high HCO3 group only in
terms of a higher anion gap (P < 0.001), slightly elevated
phosphate and BUN (P < 0.1), and marginally significant
lower membrane permeability and higher UF response.
In APD patients, those with HCO3 lower than 22 had
higher BUN, anion gap, and phosphate than the other two
groups, but only the anion gap was significantly different
from the intermediate HCO3 group (P < 0.01) (Figs. 7
and 8). BUN, anion gap, and phosphate were significantly
different from the higher HCO3 group (P < 0.01). Fur-
thermore, albumin levels were higher than the other two
groups but were statistically different only compared with
the high HCO3 group (P < 0.024) (Fig. 9). Unlike pa-
tients on CAPD, the three groups were not distinct in
peritoneal membrane characteristics and ultrafiltration
response. Patients in the intermediate HCO3 group dif-
fered from the high HCO3 group only in terms of a higher
anion gap (P < 0.001) and higher BUN (P < 0.01).
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Table 6. APD biochemical profile by HCO3 status
Parameter HCO3<22 22 ≤ HCO3<28 HCO3≥28
N% 8 (10.4%) 48 (62.3%) 21 (27.3%)
BUN mg/dL 60.4 ± 6.3 50.9 ± 2.3 40.9 ± 2.7
Creatinine mg/dL 12.6 ± 1.8 11.1 ± .6 9.9 ± .8
Na mEq/L 135.7 ± 1.8 138.9 ± .4 138.8 ± .9
K mEq/L 4.19 ± .22 3.76 ± .08 3.83 ± .15
Cl mEq/L 93.2 ± 1.4 96.0 ± .5 95.6 ± .9
HCO3 mEq/L 21.0 ± .2 25.3 ± .2 30.0 ± .5
AGAP mEq/L 25.7 ± 1.1 21.4 ± .6 17.0 ± .7
Ca mg/dL 8.8 ± .34 9.3 ± .13 9.5 ± .17
PO4 mg/dL 6.3 ± .7 5.2 ± .2 4.5 ± .3
Albumin g/dL 3.4 ± .12 3.28 ± .07 3.15 ± .10
Cholesterol mg/dL 210 ± 12 195 ± 6 209 ± 10
Data are mean ± SE. Abbreviations are: BUN, blood urea nitrogen; Na,
sodium; K, potassium; Cl, chloride; HCO3, bicarbonate; AGAP, anion gap; Ca,
calcium; PO4, phosphate.
Table 7. APD renal and dialytic profile by HCO3 status
Parameter HCO3<22 22 ≤ HCO3<28 HCO3≥28
N% 8 (10.4%) 48 (62.3%) 21 (27.3%)
Urine volume mL/24 hr 410 ± 107 515 ± 74 567 ± 181
CrCl mL/min .92 ± .41 2.48 ± .71 2.40 ± .74
Urea Cl mL/min .58 ± .26 .92 ± .25 1.32 ± .44
RRF mL/min .75 ± .34 1.70 ± .44 1.86 ± .59
Dialysis volume mL/24 hr 13636 ± 812 14106 ± 389 14835 ± 736
4-hour D/Pcreatinine .66 ± .03 .70 ± .01 .68 ± .02
D4/D0glucose .40 ± .02 .41 ± .03 .36 ± .02
4-hour D/Purea .88 ± .03 .90 ± .01 .89 ± .02
PET-UF mL/4 hr 413 ± 63 364 ± 33 280 ± 59
LD-UF mL 304 ± 169 315 ± 56 262 ± 74
Data are mean ± SE. Abbreviations are: CrCl, creatinine clearance;
urea Cl, urea clearance; RRF, average of creatinine and urea clearances;
4-hour D/Pcreatinine, ratio of dialysate creatinine at 4 hours of dwell to serum
creatinine; D4/D0glucose, ratio of 4-hour dialysate glucose to 0 hour dialysate glu-
cose; 4 hour D/Purea, ratio of dialysate urea at 4 hours of dwell to BUN; PET-UF,
net ultrafiltration during a 4-hour PET with 2.5% dextrose solution; LD-UF, net
ultrafiltration during an overnight dwell with 2.5% dextrose solution.
Because categorization by HCO3 status is empiric and
arbitrary, we further explored whether HCO3 as a con-
tinuous variable was correlated with other parameters of
biochemical control. In patients on CAPD, there was an
inverse correlation between HCO3 and BUN (r =−0.355,
P < 0.001), albumin (r = −0.194, P < 0.01), and phos-
phate levels (r = −0.279, P < 0.001). A direct correlation
was found between HCO3 and peritoneal transport as re-
flected in the four-hour D/Pcreatinine (r = 0.245, P < 0.001).
No correlation was found between HCO3 and serum cre-
atinine or any measure of renal clearance (CrCl, urea Cl,
or RRF). In CAPD patients, a significant correlation was
found between the anion gap and each of the following
parameters: BUN (r = 0.429, P < 0.001), albumin (r =
0.403, P < 0.001), serum creatinine (r = 0.362, P < 0.001),
four-hour D/Pcreatinine (r = −0.319, P < 0.001), phosphate
(r = 0.470, P < 0.001), and measures of renal clearance
[CrCl (r = −0.371, P < 0.001), urea Cl (r = −0.386, P <
0.001), and RRF (r = −0.393, P < 0.001)].
In patients on APD, there was an inverse correlation
found only between HCO3 and BUN (r = −0.37155,
P < 0.001) and phosphate levels (r = −0.336, P < 0.005).
No correlation was found between HCO3 and peritoneal
transport as reflected in the four-hour D/Pcreatinine. No
correlation was found between HCO3 and serum creati-
nine or serum albumin or any measure of renal clearance
(CrCl, urea Cl, or RRF). In APD patients, a significant
correlation was found between the anion gap and each
of the following parameters: BUN (r = 0.382, P < 0.001),
albumin (r = 0.543, P < 0.001), serum creatinine (r =
0.306, P < 0.01), phosphate (r = 0.395, P < 0.001), and
urea Cl (r = −0.294, P < 0.001). Unlike CAPD patients,
no correlation was found in APD patients between the
anion gap and peritoneal transport profile, and the cor-
relations with measures of renal clearance were of lower
value and significant only for urea clearance.
Profile by transport status
To gain further insight into the impact of peritoneal
transport status on biochemical parameters, the CAPD
and APD groups were divided into four subsets corre-
sponding to the standard definitions of transport sub-
types by PET. In CAPD patients, no notable differences
were observed between the four subgroups with respect
to BUN, creatinine, electrolytes, calcium, and cholesterol
(Tables 8 and 9). The only significant difference in HCO3
levels was between high transporters and low-average
transporters (P < 0.007), but considering the proximity of
the values for the four subgroups it is not likely to repre-
sent a clinically meaningful finding. A tendency for phos-
phate levels to increase with declining peritoneal perme-
ability parameters was observed with the difference be-
tween high, high-average, and low-average of borderline
statistical significance (P < 0.08), but attaining statistical
significance compared to low transporters (P < 0.02). A
similar tendency for the anion gap to increase with declin-
ing peritoneal permeability was also observed and was
statistically significant between high and high-average
(P < 0.017), high and low-average (P < 0.002), and
marginally significant between high-average and low-
average (P = 0.06). The trend for increasing serum albu-
min with diminishing peritoneal permeability was statis-
tically significant for all comparisons (P < 0.001). Among
CAPD patients, peritoneal transport profile did not have
an effect on measures of renal function, but, as expected,
was manifest in the parameter of peritoneal transport and
ultrafiltration. Ultrafiltration during the PET and during
the overnight dwell with 2.5% dextrose showed a ten-
dency to increase with declining peritoneal permeability
measures.
In patients on APD, statistically significant differences
in biochemical profile were not found in intergroup com-
parisons for any of the biochemical markers measured
(Tables 9 and 10). This may have been due to the small
size of the two groups (high and low transporters) repre-
sented in the sample.
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(CAPD) and automated peritoneal dialysis (APD) patients.
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Fig. 9. Albumin values were lower in patients with higher peritoneal equilibration test (PET) categories in both continuous ambulatory peritoneal
dialysis (CAPD) and automated peritoneal dialysis (APD) patients. The differences, however, were more marked in CAPD patients.
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Table 8. CAPD biochemical profile by transport status
Parameter High High Avg. Low Avg. Low
N% 25 75 66 8
BUN mg/dL 46.5 ± 3.3 50.9 ± 1.7 52.3 ± 2.2 55.1 ± 7.3
Creatinine mg/dL 9.2 ± .7 9.7 ± .3 9.6 ± .5 10.9 ± 1.5
Na mEq/L 137.6 ± .6 137.9 ± .4 137.6 ± .5 137.2 ± .9
K mEq/L 3.83 ± .15 3.90 ± .08 3.90 ± .08 4.25 ± .29
Cl mEq/L 95.7 ± .9 95.3 ± .4 94.6 ± .6 93.9 ± 1.7
HCO3 mEq/L 26.6 ± .6 25.4 ± .4 24.6 ± .4 25.6 ± 1.1
AGAP mEq/L 19.1 ± .7 21.0 ± .4 22.3 ± .6 21.6 ± 1.1
Ca mg/dL 9.2 ± .20 9.4 ± .10 9.6 ± .09 9.6 ± .27
PO4mg/dL 4.5 ± .2 5.1 ± .1 5.2 ± .2 5.7 ± .5
Albumin g/dL 2.62 ± .11 3.15 ± .05 3.44 ± .04 3.66 ± .09
Cholesterol mg/dL 198 ± 10 203 ± 5 216 ± 6 183 ± 13
Data are mean ± SE. Abbreviations are: BUN, blood urea nitrogen; Na,
sodium; K, potassium; Cl, chloride; HCO3, bicarbonate; AGAP, anion gap; Ca,
calcium; PO4, phosphate.
Because categorization by PET category is empiric and
arbitrary, we further explored whether measures of peri-
toneal permeability as continuous variables were corre-
lated with other parameters of biochemical control. In
CAPD patients, four-hour D/Pcreatinine was significantly
inversely correlated with BUN (r = −0.179, P < 0.05),
albumin (r = −0.591, P < 0.001), anion gap (r = −0.319,
P < 0.001), and phosphate (r = −0.194, P < 0.012), and
directly correlated with HCO3 (r = 0.245, P < 0.01). A
similar pattern was observed for four-hour D/D0 glu-
cose, which was significantly correlated with albumin
(r = 0.506, P < 0.001), anion gap (r = 0.320, P < 0.001),
and phosphate (r = 0.183, P < 0.02), and inversely cor-
related with HCO3 (r = −0.208, P < 0.01). The correla-
tions of four-hour D/P urea with biochemical measures
was similar to that of four-hour D/Pcreatinine, but of lower
magnitude.
In patients on APD, no correlations were found be-
tween any of the peritoneal permeability parameters and
measures of biochemical control.
DISCUSSION
The findings of this study can be summarized as follows:
(1) Patients on PD have, as a group, adequate correction
of acidosis as reflected by normal mean bicarbonate lev-
els; (2) the correction of acidosis in PD appears to be
predominantly achieved by the continuous supplemen-
tation of alkali via dialysis with RRF not differentiating
the degree of correction; (3) steady-state serum bicarbon-
ate in patients on CAPD appears to be responsive to the
underlying peritoneal membrane permeability character-
istics of the patient which govern alkali loss and gain, but
the higher dialysate volumes in APD appear to override
this effect; and (4) higher albumin, BUN, and phosphate
in patients with lower HCO3 suggest a discrepancy be-
tween daily acid load and dialysis dose as the latter is usu-
ally adjusted to the uninformative Kt/V measure rather
than indices of metabolic correction.
The observation that the majority of patients on ei-
ther CAPD or APD had adequate correction of their
metabolic acidosis does not corroborate statements made
in the literature about the status of acidosis correction in
these populations. Indeed, the statements of “lack of full
correction of metabolic acidosis” [1] in reference to the
use of 40 mmol/L lactate are dated as they reference stud-
ies in the early 1980s [31] and do not represent the con-
temporary status, particularly in view of the higher dose
of dialysis used currently [21]. The results of the present
study also call into doubt the representativeness of re-
cent studies that show values for bicarbonate in patients
on lactate-based solutions significantly lower than those
observed in current North American practice [3]. These
aberrantly lower values have been used as reference for
comparative efficiency of dialysis solutions with different
alkali preparations, which is clearly problematic.
The present report represents the largest database of
the status of acidosis correction in patients on CAPD
and APD. Our findings are consistent with several publi-
cations in the literature of smaller series. Kung et al [32]
reported mean HCO3 values of 25.9 mEq/L in 43 patients,
with nine patients having values lower than 22, a propor-
tion slightly higher than ours. Dumler and Gallan [33]
described values of HCO3 of 25 ± 4 mEq/L, stable over a
one-year period of observation with 13 of 80 patients hav-
ing values lower than 22 mEq/L. Interestingly, Kung et al
[32] found that the lowest values of HCO3 were seen in
well nourished patients (as assessed by subjective global
assessment [SGA]), suggesting that a higher food intake
may be responsible for an acid load higher than the rate of
alkali replenishment by dialysis. Higher values for BUN
and albumin were also observed in the Korean patients
with the lowest HCO3. Kang et al [34] found a negative
correlation between nPNA and HCO3, suggesting that
increased dietary acid load is responsible for the lower
HCO3.
The elevation of the anion gap would not be surprising
in patients with untreated uremic metabolic acidosis as it
is a hallmark of the condition. The persistent elevation
in the face of normal bicarbonate levels invites further
scrutiny [35]. While the correlation between the anion
gap and serum bicarbonate is expected for the condition,
the curve is “shifted upward” because of the normal lev-
els of bicarbonate. The increase in the anion gap cannot
in this case be explained by decreased cations as the con-
centrations of K and Ca were normal, and Mg, while not
measured in the present study, is not likely to be low in pa-
tients with advanced renal failure. Additionally, uniden-
tified anions of a hyperosmolar state can also be ruled
out. Elevations in either inorganic anions (phosphate and
sulfate) or organic anions (lactate, ketones, and uremic
organic anions of various identities) must be invoked as
residual causality factors. Phosphate levels were elevated
in these patients and correlated with the anion gap. While
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Table 9. CAPD renal and dialytic profile by transport status
Parameter High High Avg. Low Avg. Low
N% 25 75 66 8
Urine volume mL/24 hr 564 ± 126 872 ± 103 650 ± 78 443 ± 121
CrCl mL/min 3.60 ± 1.11 5.15 ± .69 5.92 ± .79 4.26 ± 1.17
Urea Cl mL/min 1.70 ± .45 2.87 ± .35 2.59 ± .29 1.68 ± .51
RRF mL/min 2.65 ± .77 4.01 ± .51 4.26 ± .51 2.97 ± .83
Dialysis volume mL/24 hr 9780 ± 374 9406 ± 175 9233 ± 161 8500 ± 327
4-hour D/Pcreatinine .88 ± .01 .71 ± .01 .58 ± .01 .44 ± .03
D4/D0glucose .26 ± .01 .37 ± .01 .44 ± .01 .44 ± .03
4-hour D/Purea .98 ± .01 .92 ± .00 .85 ± .01 .72 ± .06
PET-UF mL/4 hr 250 ± 33 449 ± 25 472 ± 25 594 ± 51
LD-UF mL 133 ± 69 216 ± 45 416 ± 38 492 ± 81
Data are mean ± SE. Abbreviations are: CrCl, creatinine clearance; urea Cl, urea clearance; RRF, average of creatinine and urea clearances; 4-hour D/Pcreatinine,
ratio of dialysate creatinine at 4 hours of dwell to serum creatinine; D4/D0glucose, ratio of 4-hour dialysate glucose to 0 hour dialysate glucose; 4-hour D/Purea, ratio of
dialysate urea at 4 hours of dwell to BUN; PET-UF, net ultrafiltration during a 4-hour PET with 2.5% dextrose solution; LD-UF, net ultrafiltration during an overnight
dwell with 2.5% dextrose solution.
Table 10. APD biochemical profile by transport status
Parameter High High Avg. Low Avg. Low
N% 6 43 24 4
BUN mg/dL 50.3 ± 8.2 50.3 ± 2.7 48.25 ± 2.69 59.0 ± 10.6
Creatinine mg/dL 10.76 ± 1.37 10.85 ± .64 10.61 ± .78 14.6 ± 3.9
Na mEq/L 137.8 ± .75 138.6 ± .57 138.25 ± .96 137.5 ± 1.19
K mEq/L 4.05 ± .12 3.86 ± .09 3.70 ± .12 4.33 ± .14
Cl mEq/L 96.17 ± 1.56 96.12 ± .65 94.38 ± .78 93.75 ± .48
HCO3 mEq/L 25.77 ± .94 25.70 ± .56 25.88 ± .52 25.13 ± 1.73
AGAP mEq/L 19.95 ± 2.4 20.55 ± .68 21.69 ± .75 22.97 ± 4.58
Ca mg/dL 9.55 ± .38 9.18 ± .13 9.50 ± .17 8.95 ± .72
PO4 mg/dL 4.82 ± .66 5.29 ± .24 5.03 ± .34 6.20 ± 1.46
Albumin g/dL 3.08 ± .31 3.25 ± .075 3.31 ± .08 3.55 ± .22
Cholesterol mg/dL 207 ± 21 199 ± 6 199 ± 8 204 ± 23
Data are mean ± SE. Abbreviations are: BUN, blood urea nitrogen; Na, sodium; K, potassium; Cl, chloride; HCO3, bicarbonate; AGAP, anion gap; Ca, calcium;
PO4, phosphate.
Table 11. APD renal and dialytic profile by transport status
Parameter High High Avg. Low Avg. Low
N% 6 43 24 4
Urine volume mL/24 hr 516 ± 121 582 ± 94 420 ± 90 230 ± 0
CrCl mL/min 2.1 ± 1.1 2.8 ± .8 1.5 ± .5 .9 ± .9
Urea Cl mL/min 1.0 ± .5 1.2 ± .3 .65 ± .22 .26 ± .26
RRF mL/min 1.5 ± .8 1.9 ± .5 1.1 ± .4 .59 ± .59
Dialysis volume mL/24 hr 15600 ± 1095 14104 ± 480 13862 ± 366 14625 ± 1724
4-hour D/Pcreatinine .87 ± .02 .72 ± .01 .61 ± .01 .40 ± 0
D4/D0glucose .25 ± .02 .38 ± .02 .47 ± .04 .36 ± .01
4-hour D/Purea .99 ± .01 .92 ± .01 .85 ± .02 .6 ± 0
PET-UF mL/4 hr 168 ± 60 339 ± 29 404 ± 57 441 ± 141
LD-UF mL 99 ± 73 289 ± 62 375 ± 68 329 ± 370
Data are mean ± SE. Abbreviations are: CrCl, creatinine clearance; urea Cl, urea clearance; RRF, average of creatinine and urea clearances; 4-hour D/Pcreatinine,
ratio of dialysate creatinine at 4 hours of dwell to serum creatinine; D4/D0glucose, ratio of 4-hour dialysate glucose to 0 hour dialysate glucose; 4 hour D/Purea, ratio of
dialysate urea at 4 hours of dwell to BUN; PET-UF, net ultrafiltration during a 4-hour PET with 2.5% dextrose solution; LD-UF, net ultrafiltration during an overnight
dwell with 2.5% dextrose solution.
these patients were on lactate-containing dialysis fluid,
the likelihood of an elevation in serum lactate in stable
patients on PD is extremely remote. The load of lactate
absorbed in PD is greatly inferior to the rate of production
of lactic acid in normal humans (15 to 30 mEq/kg/day),
and elevation in serum lactate has not been reported in
patients on PD [36]. The inclusion criteria for the study
also rule out ketones as a source of organic anions. We
are therefore left with the inorganic anions [phosphate
(documented) and sulfate (assumed)] and the elevation
in organic uremic anions. The low albumin concentration
observed in these patients, while typical of patients on
dialysis in North America, is expected to lead to a nar-
rowing of the anion gap. Indeed, the correlation between
serum albumin and serum anion gap confirms this expec-
tation (Fig. 4). The lowest anion gap values are observed
in the patients with the lowest albumin. A correction
of the anion gap for the decline in albumin would have
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resulted in higher values for the anion gap in the majority
of subjects in this study. Finally, some of the increase in the
anion gap may be due to the level of alkalosis observed
in some patients, as alkalosis affects the charge on serum
albumin. It is interesting to note, however, that the lowest
levels of anion gap were observed in the patients with the
highest values of serum bicarbonate (Fig. 3). The combi-
nation of a low anion gap and high bicarbonate may imply
that the acid burden from diet and metabolism is lower
than alkali gain from dialysis and may identify patients
with lower dietary protein intake.
Correlations between the anion gap and other bio-
chemical measures in patients on PD were previously
explored by Dumler et al [37]. They found a direct corre-
lation (P < 0.0001) between anion gap and serum albu-
min (R = 0.402), BUN (R = 0.488), and serum creatinine
(R = 0.473) concentrations [37]. These authors used a
definition of acidosis based exclusively on the elevation
in anion gap [37]. However, as our analysis illustrates, the
relationship between bicarbonate and anion gap is shifted
in such a way that an elevated anion gap will continue to
be observed in these patients despite a normalization of
the metabolic acidosis.
The impact of the PD modality used (CAPD vs. APD)
on acid base balance has been invoked as unexplored in
recent reviews [13]. The present study serves to address
this issue in that it shows equal correction of metabolic
acidosis in both modalities of PD. The use of short cycles
in APD nighttime period may be expected to alter the ki-
netics of buffer exchange (discussed in a separate paper
in this supplement), but the net overall effect of acido-
sis correction appears to be identical. In neither group
did the level of residual renal function influence acid-
base status, suggesting that the provision of alkali via PD
overrides quantitatively the small contribution of RRF.
There were differences, however, observed in the rela-
tionships between certain measures of acid-base status
and transport characteristics that were different between
CAPD and APD. These were notably the independence
of HCO3 levels in APD from the patient transport status
and their dependence on peritoneal permeability in pa-
tients on CAPD. This may relate to the higher dialysate
volume and, hence, alkali exposure in patients on APD.
APD patients are recurrently exposed to high lactate con-
centrations by virtue of the solution replenishment during
frequent short exchanges during the nocturnal phase of
the therapy. In patients on CAPD, peritoneal transport
status appeared to be correlated with HCO3 levels, BUN,
albumin, and the anion gap.
In both CAPD and APD, lower levels of HCO3 were
observed in association with higher BUN and phosphate,
suggesting a slight discrepancy between the acid burden
(reflected in the high BUN and phosphate from pro-
tein catabolism) and the dialytic provision of alkali. It
is plausible that, had dialysis dose been directed at gen-
eral metabolic correction rather than a fixed Kt/V target,
such a discrepancy may have been bridged. Kt/V is no-
toriously uninformative when used as the sole guidance
for dialysis dose. The source of higher acid load was also
associated with higher albumin level reflecting likely a
better nutritional status.
CONCLUSION
Patients on PD have as a group adequate correction of
acidosis as reflected by normal mean bicarbonate levels.
The correction of acidosis in PD appears to be predom-
inantly achieved by the continuous supplementation of
alkali via dialysis with RRF not differentiating the degree
of correction. Steady-state serum bicarbonate in patients
on CAPD appears to be responsive to the underlying
peritoneal membrane permeability characteristics of the
patient that govern alkali loss and gain, but the higher
dialysate volumes in APD appear to override this effect.
Higher albumin, BUN, and phosphate in patients with
lower HCO3 suggest a discrepancy between daily acid
load and dialysis dose, as the latter is usually adjusted
to the uninformative Kt/V measure rather than indices
of metabolic correction. Adjustment of dialysis dose to
achieve full metabolic correction needs to be considered.
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